Washington, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): January 17, 2003

                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

           Delaware                   000-14879                  222322400
(State or Other Jurisdiction   (Commission File Number)        (IRS Employer
     of Incorporation)                                       Identification No.)

650 College Road East, 3rd Floor, Princeton, NJ                         08540
(Address of Principal Executive Offices)                              (Zip Code)

                                 (609) 750-8200
                         (Registrant's telephone number,
                              including area code)

          (Former Name or Former Address, if Changed Since Last Report)

     Item 5.     Other Events and Required FD Disclosure.

Product Update

On January 17, 2003,  Cytogen  Corporation  (the  "Company")  and DRAXIMAGE Inc.
("DRAXIMAGE"), the radiopharmaceutical subsidiary of DRAXIS Health Inc., jointly
issued a press release  reporting that the production and sales of the Palladium
version of BrachySeed(TM) have been halted for an unspecified period of time.
Production and sales of the Iodine-125 version of BrachySeed are continuing

BrachySeed Pd-103 was launched  commercially by Cytogen in May 2002 and is still
in its early launch phase.  Cytogen and DRAXIMAGE are discussing ways to resolve
issues surrounding Palladium BrachySeed production and sales.

In December  2000,  Cytogen  entered into a 10-year  agreement with DRAXIMAGE to
market and  distribute  BrachySeed  Iodine and Palladium  implants in the United
States for the treatment of prostate  cancer in exchange for a transfer price on
seeds  sold  plus  royalties  on sales  and  certain  milestone  payments.  Both
companies'  decision to enter the brachytherapy field together was predicated on
the successful launch of both the Iodine and Palladium brachytherapy products.

Such press release is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.  The foregoing  description  of such press release is qualified in
its entirety by reference to such document.

     Item 7.     Financial Statements, Pro Forma Financial Information and

     (c)  Exhibits.

              Exhibit No.    Description
              -----------    -----------
                 99.1        Press release of the Company dated January 17, 2003


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                       Cytogen Corporation

                                       By:  /s/ Michael D. Becker
                                           Michael D. Becker
                                           President and Chief Executive Officer

Date:  January 17, 2003